J. B. Chemicals & Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

J. B. Chemicals & Pharmaceuticals şirketinin toplam hissedar öz sermayesi ₹29.2B ve toplam borcu ₹3.8B olup, bu da borç-öz sermaye oranını 12.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹39.9B ve ₹10.7B dir. J. B. Chemicals & Pharmaceuticals 'in FAVÖK'ü ₹7.9B faiz karşılama oranı 24.2 dur. Şirketin ₹4.6B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

12.9%

Borç/özkaynak oranı

₹3.78b

Borç

Faiz karşılama oranı	24.2x
Nakit	₹4.60b
Eşitlik	₹29.23b
Toplam yükümlülükler	₹10.71b
Toplam varlıklar	₹39.94b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 506943 'nin kısa vadeli varlıkları ( ₹18.5B ) kısa vadeli yükümlülüklerini ( ₹8.7B ) aşıyor.

Uzun Vadeli Yükümlülükler: 506943 şirketinin kısa vadeli varlıkları ( ₹18.5B ) uzun vadeli yükümlülüklerini ( ₹2.0B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 506943 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 506943 şirketinin borç/öz sermaye oranı son 5 yılda 1.7% seviyesinden 12.9% seviyesine yükseldi.

Borç Kapsamı: 506943 'nin borcu işletme nakit akışı ( 208.9% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 506943 'in borcuna ilişkin faiz ödemeleri EBIT ( 24.2 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

J. B. Chemicals & Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

J. B. Chemicals & Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 06, 2024

Vice President of HR & Administration recently sold ₹5.8m worth of stock

Insider recently sold ₹2.1m worth of stock

Alkem Reportedly Joins $3 Billion Race for JB Chem as Torrent Pauses Talks

Insider recently sold ₹7.2m worth of stock

Key Executive recently sold ₹1.4m worth of stock

J. B. Chemicals & Pharmaceuticals Limited Approves Final Dividend for the Year Ended March 31, 2024

Torrent Pharma Reportedly is Said to Seek Raising $3 Billion for KKR's Stake in JB Chemicals

Torrent Pharmaceuticals Reportedly in Talks to Acquire KKR’s Stake in JB Chemicals

Full year 2024 earnings: EPS misses analyst expectations

Final dividend of ₹6.75 announced

J. B. Chemicals & Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024

Insider recently sold ₹876k worth of stock

J. B. Chemicals & Pharmaceuticals Limited, Annual General Meeting, Aug 21, 2024

Insider recently sold ₹1.1m worth of stock

Full year 2024 earnings: EPS misses analyst expectations

J. B. Chemicals & Pharmaceuticals Limited Recommends Final Dividend for the Year 2023-2024

J. B. Chemicals & Pharmaceuticals Limited to Report Q4, 2024 Results on May 17, 2024

President of Global Business recently sold ₹5.6m worth of stock

Insider recently sold ₹3.2m worth of stock

Insider recently sold ₹2.3m worth of stock

KKR Reportedly Considers Selling Controlling Stake in JB Pharma

President of India Business recently sold ₹6.8m worth of stock

Price target increased by 7.1% to ₹1,870

Upcoming dividend of ₹5.50 per share at 0.6% yield

Dividend of ₹5.50 announced

J. B. Chemicals & Pharmaceuticals Limited Declares Interim Dividend for Financial Year 2023-24

J. B. Chemicals & Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Price target increased by 7.6% to ₹1,700

Price target increased by 8.4% to ₹1,677

Less than half of directors are independent

J. B. Chemicals & Pharmaceuticals Limited Appoints Akshay Tanna as an Additional Director

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

J. B. Chemicals & Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023

Price target increased by 17% to ₹1,606

CEO & Whole-Time Director recently sold ₹35m worth of stock

Investor sentiment deteriorates as stock falls 48%

J. B. Chemicals & Pharmaceuticals Limited Announces Cessation of Lakshay Kataria, Chief Financial Officer and Key Managerial Personnel, Effective November 30, 2023

CEO & Whole-Time Director recently sold ₹40m worth of stock

J. B. Chemicals & Pharmaceuticals Limited Approves Final Dividend for the Year Ended March 31, 2023

J.B. Chemicals & Pharmaceuticals Limited Announces Abbreviated New Drug Application Approval by US FDA

CEO & Whole-Time Director recently sold ₹40m worth of stock

Price target increased by 8.1% to ₹2,556

Upcoming dividend of ₹9.25 per share at 0.7% yield

J. B. Chemicals & Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS misses analyst expectations

CEO & Whole-Time Director recently sold ₹32m worth of stock

J. B. Chemicals & Pharmaceuticals Limited Recommends Final Dividend for the Year 2022-2023

Full year 2023 earnings: EPS misses analyst expectations

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹2.2m worth of stock

Insider recently sold ₹2.7m worth of stock

CEO & Whole-Time Director recently sold ₹20m worth of stock

CEO & Whole-Time Director recently sold ₹9.8m worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

J. B. Chemicals & Pharmaceuticals Limited Declares Interim Dividend

J. B. Chemicals & Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 08, 2023

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) completed the acquisition of Razel Franchise For India And Nepal Region from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK).

CEO & Whole-Time Director recently sold ₹10m worth of stock

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Razel Franchise For India And Nepal Region from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR3.1 billion.

JB Chemicals & Pharmaceuticals Limited (JB Pharma) Receives ANDA Approval For Venlafaxine Hydrochloride Extended-Release Tablets From USFDA

Price target increased to ₹2,292

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹14.37 (vs ₹12.65 in 2Q 2022)

J. B. Chemicals & Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022

President of Global Business recently sold ₹7.0m worth of stock

CEO & Whole-Time Director recently sold ₹32m worth of stock

Torrent Pharma Reportedly Set to Acquire Curatio

Insider recently sold ₹1.3m worth of stock

Upcoming dividend of ₹8.00 per share

Full year 2022 earnings: EPS misses analyst expectations

J. B. Chemicals & Pharmaceuticals Limited Proposes Final Dividend for the Financial Year 2021-22, Payable on or After September 1, 2022

J. B. Chemicals & Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 04, 2022

J. B. Chemicals & Pharmaceuticals Limited, Annual General Meeting, Aug 24, 2022

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.